Replimune Group Inc., a clinical-stage biotechnology company headquartered in Woburn, Massachusetts, is dedicated to the discovery and development of oncolytic immunotherapy for cancer treatment. Operating within the health care sector, Replimune Group Inc. focuses on innovative therapies aimed at improving outcomes for patients with cancer diseases. The company’s efforts are concentrated on leveraging the body’s immune system to combat cancer, positioning itself at the forefront of biotechnological advancements in oncology.
As of May 27, 2026, Replimune Group Inc. is listed on the Nasdaq stock exchange, with a closing price of $4.68. The company’s market capitalization stands at approximately $388.09 million. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $13.24 on July 20, 2025, and a 52-week low of $1.50 on April 12, 2026. This fluctuation reflects the dynamic nature of the biotechnology sector and the challenges inherent in clinical-stage development.
The company’s financial metrics indicate a price-to-earnings (P/E) ratio of -1.37, which is not uncommon for companies in the clinical development phase, as they may not yet be generating profits. This metric underscores the speculative nature of investing in companies that are still in the process of developing and testing their therapies.
Replimune Group Inc. was established with an initial public offering (IPO) on July 20, 2018. Since then, the company has been actively engaged in advancing its pipeline of oncolytic immunotherapies. These therapies are designed to selectively target and destroy cancer cells while sparing healthy tissue, offering a promising approach to cancer treatment.
The company’s operations are primarily based in the United States, where it serves its customer base. For those interested in learning more about Replimune Group Inc.’s activities, offerings, and the progress of its clinical trials, additional information is available on their official website at www.replimune.com .
In summary, Replimune Group Inc. remains committed to its mission of developing cutting-edge immunotherapies for cancer patients. Despite the inherent risks and challenges of the biotechnology industry, the company continues to pursue its goal of bringing innovative treatments to market, with the potential to significantly impact the field of oncology.
